Skip to main content
Erschienen in: Journal of Neural Transmission 5/2012

01.05.2012 | Basic Neurosciences, Genetics and Immunology - Original Article

Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes

verfasst von: Eszter Lajkó, Lívia Polgár, Orsolya Láng, József Lengyel, László Kőhidai, Kálmán Magyar

Erschienen in: Journal of Neural Transmission | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Selegiline (R-deprenyl), a monoamine oxidase-B (MAO-B) inhibitor, has complex pharmacological effect that contributes to treatment of neurodegenerative diseases such as Parkinson’s and presumably Alzheimer’s disease and might work as an inhibitor of tumor growth. In respect of tumorigenesis and metastasis formation, the controlled modifications of adhesion and migration have high therapeutic significance. In the present study, our purpose was to investigate cell physiological responses (adhesion, chemotaxis and proliferation) induced by selegiline, its metabolites and synthetic derivatives and to find some correlations between the molecular structure and the reported antitumor behavior of the derivatives. Our results demonstrated that both R- and S-deprenyls have the potency to elicit increased adhesion and a chemorepellent activity in monocyte model (Mono Mac 6 cell line derived from monoblastic leukemia); however, only the R-enantiomer proved to be cytotoxic. Among the metabolites R-amphetamine has retained the adhesion inducer and the chemorepellent effect of the parent drug on the most significant level. In contrast, a reversed chemotactic effect and an improved cytotoxic character were detected in the presence of fluoro group (p-fluoro-S-deprenyl). In summary, the adhesion inducer activity, chemorepellent and advantageous cytotoxic effects of selegiline and some derivatives indicate that these drug molecules might have inhibitory effects in metastasis formation in primary tumors.
Literatur
Zurück zum Zitat Atienza JM, Zhu J, Wang X, Xu X, Abassi Y (2005) Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 10:795–805PubMedCrossRef Atienza JM, Zhu J, Wang X, Xu X, Abassi Y (2005) Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 10:795–805PubMedCrossRef
Zurück zum Zitat Barrett JS, Hochadel TJ, Morales RJ, Rohatagi S, DeWitt KE, Watson SK, DiSanto AR (1996a) Pharmacokinetics and safety of a selegiline transdermal system relative to single dose oral administration in the elderly. Am J Ther 3:688–698PubMedCrossRef Barrett JS, Hochadel TJ, Morales RJ, Rohatagi S, DeWitt KE, Watson SK, DiSanto AR (1996a) Pharmacokinetics and safety of a selegiline transdermal system relative to single dose oral administration in the elderly. Am J Ther 3:688–698PubMedCrossRef
Zurück zum Zitat Barrett JS, Szego P, Rohatagi S, Morales RJ, DeWitt KE, Rajewski G, Ireland J (1996b) Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res 13:1535–1540PubMedCrossRef Barrett JS, Szego P, Rohatagi S, Morales RJ, DeWitt KE, Rajewski G, Ireland J (1996b) Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res 13:1535–1540PubMedCrossRef
Zurück zum Zitat Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti- akinetic effect after l-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36:303–326PubMedCrossRef Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti- akinetic effect after l-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36:303–326PubMedCrossRef
Zurück zum Zitat Birkmayer W, Riederer P, Ambrozi L, Youdim MB (1977) Implications of combined treatment with ‘Madopar’ and l-deprenyl in Parkinson’s disease. A long-term study. Lancet 1:439–443PubMedCrossRef Birkmayer W, Riederer P, Ambrozi L, Youdim MB (1977) Implications of combined treatment with ‘Madopar’ and l-deprenyl in Parkinson’s disease. A long-term study. Lancet 1:439–443PubMedCrossRef
Zurück zum Zitat Birkmayer W, Knoll J, Riederer P, Youdim MB (1983) (—)-Deprenyl leads to prolongation of l-dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatry 19:170–176PubMed Birkmayer W, Knoll J, Riederer P, Youdim MB (1983) (—)-Deprenyl leads to prolongation of l-dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatry 19:170–176PubMed
Zurück zum Zitat Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J (1985) Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64:113–127PubMedCrossRef Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J (1985) Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64:113–127PubMedCrossRef
Zurück zum Zitat Buu NT, Angers M, Duhaime J, Kuchel O (1987) Modification of dopamine and norepinephrine metabolism in the rat brain by monoamine oxidase inhibitors. J Neural Transm 70:39–50PubMedCrossRef Buu NT, Angers M, Duhaime J, Kuchel O (1987) Modification of dopamine and norepinephrine metabolism in the rat brain by monoamine oxidase inhibitors. J Neural Transm 70:39–50PubMedCrossRef
Zurück zum Zitat Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (−)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48:517–521PubMedCrossRef Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (−)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48:517–521PubMedCrossRef
Zurück zum Zitat Clement B, Behrens D, Möller W, Cashman JR (2000) Reduction of amphetamine hydroxylamine and other aliphatic hydroxylamines by benzamidoxime reductase and human liver microsomes. Chem Res Toxicol 13:1037–1045PubMedCrossRef Clement B, Behrens D, Möller W, Cashman JR (2000) Reduction of amphetamine hydroxylamine and other aliphatic hydroxylamines by benzamidoxime reductase and human liver microsomes. Chem Res Toxicol 13:1037–1045PubMedCrossRef
Zurück zum Zitat Erdö F, Baranyi A, Takács J, Arányi P (2000) Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils. Neuroreport 11:2597–2600PubMedCrossRef Erdö F, Baranyi A, Takács J, Arányi P (2000) Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils. Neuroreport 11:2597–2600PubMedCrossRef
Zurück zum Zitat Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, MacGregor R (1997) Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 18:431–435PubMedCrossRef Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, MacGregor R (1997) Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 18:431–435PubMedCrossRef
Zurück zum Zitat Giaever I, Keese CR (1984) Monitoring fibroblast behavior with an applied electric field. Proc Natl Acad Sci USA 81:3761–3764PubMedCrossRef Giaever I, Keese CR (1984) Monitoring fibroblast behavior with an applied electric field. Proc Natl Acad Sci USA 81:3761–3764PubMedCrossRef
Zurück zum Zitat Haberle D, Szökö E, Halász AS, Magyar K (2001) The effect of low oral dose of (−)-deprenyl and its metabolites on DSP-4 toxicity. J Neural Transm 108:1239–1247PubMedCrossRef Haberle D, Szökö E, Halász AS, Magyar K (2001) The effect of low oral dose of (−)-deprenyl and its metabolites on DSP-4 toxicity. J Neural Transm 108:1239–1247PubMedCrossRef
Zurück zum Zitat Heinonen EH, Myllyla V, Sotaniemi K (1989) Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 126:93–99 Heinonen EH, Myllyla V, Sotaniemi K (1989) Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 126:93–99
Zurück zum Zitat Jenei V, Zor K, Magyar K, Jakus J (2005) Increased cell–cell adhesion, a novel effect of R-(–)-deprenyl. J Neural Transm 112:1433–1445PubMedCrossRef Jenei V, Zor K, Magyar K, Jakus J (2005) Increased cell–cell adhesion, a novel effect of R-(–)-deprenyl. J Neural Transm 112:1433–1445PubMedCrossRef
Zurück zum Zitat Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408PubMed Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408PubMed
Zurück zum Zitat Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155:154–164PubMed Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155:154–164PubMed
Zurück zum Zitat Kőhidai L, Lajkó E, Láng O, Igaz A, Lengyel J, Magyar K (2010) Cell adhesion induced by deprenyl and its derivatives—investigations of adenocarcinoma cell lines (LM2, LM3) by ECIS technique and introduction Cell-LED® a new lighting equipment dedicated to ECIS (2010 ECIS Users Meeting, Rensselaerville, USA) Kőhidai L, Lajkó E, Láng O, Igaz A, Lengyel J, Magyar K (2010) Cell adhesion induced by deprenyl and its derivatives—investigations of adenocarcinoma cell lines (LM2, LM3) by ECIS technique and introduction Cell-LED® a new lighting equipment dedicated to ECIS (2010 ECIS Users Meeting, Rensselaerville, USA)
Zurück zum Zitat Lamensdorf I, Youdim MB, Finberg JP (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67:1532–1539PubMedCrossRef Lamensdorf I, Youdim MB, Finberg JP (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67:1532–1539PubMedCrossRef
Zurück zum Zitat Magyar K (1994) Behaviour of (−)-deprenyl and its analogues. J Neural Transm Suppl 41:167–175PubMed Magyar K (1994) Behaviour of (−)-deprenyl and its analogues. J Neural Transm Suppl 41:167–175PubMed
Zurück zum Zitat Magyar K (1997) Effect of selegiline against selective neurotoxins. Vopr Med Khim 43:504–514PubMed Magyar K (1997) Effect of selegiline against selective neurotoxins. Vopr Med Khim 43:504–514PubMed
Zurück zum Zitat Magyar K, Szende B (2004) (−)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and antiapoptotic properties. Neurotoxicology 25:233–242PubMedCrossRef Magyar K, Szende B (2004) (−)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and antiapoptotic properties. Neurotoxicology 25:233–242PubMedCrossRef
Zurück zum Zitat Magyar K, Vizi ES, Ecseri Z, Knoll J (1967) Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylam.ine (E-250). Acta Physiol Hung 32:377–387 Magyar K, Vizi ES, Ecseri Z, Knoll J (1967) Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylam.ine (E-250). Acta Physiol Hung 32:377–387
Zurück zum Zitat Magyar K, Ecseri Z, Bernáth G, Sátory É, Knoll J (1979) Structure–activity relationship of selective inhibitors of MAO-B. In: Magyar K (ed) Advances in pharmacological research and practice, proceedings of the 3rd congress of the Hungarian Pharmacological Society, Budapest, vol IV. Monoamine oxidases and their selective inhibition. Pergamon Press, Akadémiai kiadó, Budapest, pp 11–21 Magyar K, Ecseri Z, Bernáth G, Sátory É, Knoll J (1979) Structure–activity relationship of selective inhibitors of MAO-B. In: Magyar K (ed) Advances in pharmacological research and practice, proceedings of the 3rd congress of the Hungarian Pharmacological Society, Budapest, vol IV. Monoamine oxidases and their selective inhibition. Pergamon Press, Akadémiai kiadó, Budapest, pp 11–21
Zurück zum Zitat Magyar K, Szende B, Lengyel J, Tarczali J, Szatmáry I (1998) The neuroprotective and neuronal rescue effects of (−)-deprenyl. J Neural Transm Suppl 52:109–123PubMed Magyar K, Szende B, Lengyel J, Tarczali J, Szatmáry I (1998) The neuroprotective and neuronal rescue effects of (−)-deprenyl. J Neural Transm Suppl 52:109–123PubMed
Zurück zum Zitat Magyar K, Pálfi M, Tábi T, Kalász H, Szende B, Szökő E (2004) Pharmacological aspect of (−)-deprenyl. Curr Med Chem 11:2017–2031PubMed Magyar K, Pálfi M, Tábi T, Kalász H, Szende B, Szökő E (2004) Pharmacological aspect of (−)-deprenyl. Curr Med Chem 11:2017–2031PubMed
Zurück zum Zitat Mannerström M, Toimela T, Ylikomi T, Tähti H (2006) The combined use of human neuronal and liver cell lines and mouse hepatocytes improves the predictability of the neurotoxicity of selected drugs. Toxicol Lett 165:195–202PubMedCrossRef Mannerström M, Toimela T, Ylikomi T, Tähti H (2006) The combined use of human neuronal and liver cell lines and mouse hepatocytes improves the predictability of the neurotoxicity of selected drugs. Toxicol Lett 165:195–202PubMedCrossRef
Zurück zum Zitat Moh MC, Shen S (2009) The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adhesion Migr 3:334–336CrossRef Moh MC, Shen S (2009) The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adhesion Migr 3:334–336CrossRef
Zurück zum Zitat Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6:542–544PubMed Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6:542–544PubMed
Zurück zum Zitat Riederer P, Youdim MB (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 46:1359–1365PubMedCrossRef Riederer P, Youdim MB (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 46:1359–1365PubMedCrossRef
Zurück zum Zitat Schmidt S, Friedl P (2010) Interstitial cell migration: integrin-dependent and alternative adhesion mechanisms. Cell Tissue Res 339:83–92PubMedCrossRef Schmidt S, Friedl P (2010) Interstitial cell migration: integrin-dependent and alternative adhesion mechanisms. Cell Tissue Res 339:83–92PubMedCrossRef
Zurück zum Zitat Shin HS (1997) Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 25:657–662PubMed Shin HS (1997) Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 25:657–662PubMed
Zurück zum Zitat Szende B, Magyar K, Szegedi Z (2000) Apoptotic and antiapoptotic effect of (−)-deprenyl and (−)-desmethyl-deprenyl on human cell lines. Neurobiology (Bp) 8:249–255 Szende B, Magyar K, Szegedi Z (2000) Apoptotic and antiapoptotic effect of (−)-deprenyl and (−)-desmethyl-deprenyl on human cell lines. Neurobiology (Bp) 8:249–255
Zurück zum Zitat Szende B, Bökönyi G, Bocsi J, Kéri G, Timár F, Magyar K (2001) Anti-apoptotic and apoptotic action of (–)-deprenyl and its metabolites. J Neural Transm 108:25–33PubMedCrossRef Szende B, Bökönyi G, Bocsi J, Kéri G, Timár F, Magyar K (2001) Anti-apoptotic and apoptotic action of (–)-deprenyl and its metabolites. J Neural Transm 108:25–33PubMedCrossRef
Zurück zum Zitat Szende B, Barna G, Magyar K (2010) Cytoprotective effect of (−)-deprenyl, (−)desmethyl-deprenyl and (−)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells. J Neural Transm 117:695–698PubMedCrossRef Szende B, Barna G, Magyar K (2010) Cytoprotective effect of (−)-deprenyl, (−)desmethyl-deprenyl and (−)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells. J Neural Transm 117:695–698PubMedCrossRef
Zurück zum Zitat Szilágyi G, Simon L, Wappler E, Magyar K, Nagy Z (2009) (−)Deprenyl-N-oxide, a (−)deprenyl metabolite, is cytoprotective after hypoxic injury in PC12 cells, or after transient brain ischemia in gerbils. Neurol Sci 283:182–186CrossRef Szilágyi G, Simon L, Wappler E, Magyar K, Nagy Z (2009) (−)Deprenyl-N-oxide, a (−)deprenyl metabolite, is cytoprotective after hypoxic injury in PC12 cells, or after transient brain ischemia in gerbils. Neurol Sci 283:182–186CrossRef
Zurück zum Zitat Szökő É, Tábi T, Halász AS, Pálfi M, Kalász H (2004) Identification of the enantiomer form of deprenyl metabolites and deprenyl-N-oxide in Rat Urine. In: Török T, Klebovich I (eds) Monoamine oxidase inhibitors and their role in neurotransmission (drug development). Medicina Kiadó, Budapest, pp 41–54 Szökő É, Tábi T, Halász AS, Pálfi M, Kalász H (2004) Identification of the enantiomer form of deprenyl metabolites and deprenyl-N-oxide in Rat Urine. In: Török T, Klebovich I (eds) Monoamine oxidase inhibitors and their role in neurotransmission (drug development). Medicina Kiadó, Budapest, pp 41–54
Zurück zum Zitat Tatton WG, Chalmers-Redman RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (−)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47:S171–S183PubMed Tatton WG, Chalmers-Redman RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (−)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47:S171–S183PubMed
Zurück zum Zitat Tatton WG, Ju WY, Holland DP, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572–1575PubMedCrossRef Tatton WG, Ju WY, Holland DP, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572–1575PubMedCrossRef
Zurück zum Zitat Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA (1996) (−)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48:45–59PubMed Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA (1996) (−)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48:45–59PubMed
Zurück zum Zitat Tekes K, Tóthfalusi L, Gaál J, Magyar K (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol J Pharmacol Pharm 40:653–658PubMed Tekes K, Tóthfalusi L, Gaál J, Magyar K (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol J Pharmacol Pharm 40:653–658PubMed
Zurück zum Zitat Terleckyj IA, Heikkila RE (1992) In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72, 974A and fluorodeprenyl. Ann NY Acad Sci 648:365–367PubMedCrossRef Terleckyj IA, Heikkila RE (1992) In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72, 974A and fluorodeprenyl. Ann NY Acad Sci 648:365–367PubMedCrossRef
Zurück zum Zitat ThyagaRajan S, Meites J, Quadri SK (1995) Deprenyl reinitiates estrous cycles, reduces serum prolactin and decreases the incidence of mammary and pituitary tumors in old acyclic rats. Endocrinology 136:1103–1110PubMedCrossRef ThyagaRajan S, Meites J, Quadri SK (1995) Deprenyl reinitiates estrous cycles, reduces serum prolactin and decreases the incidence of mammary and pituitary tumors in old acyclic rats. Endocrinology 136:1103–1110PubMedCrossRef
Zurück zum Zitat ThyagaRajan S, Madden KS, Stevens SY, Felten DL (1999) Inhibition of tumor growth by l-deprenyl involves neural-immune interactions in rats with spontaneously developing mammary tumors. Anticancer Res 19:5023–5028PubMed ThyagaRajan S, Madden KS, Stevens SY, Felten DL (1999) Inhibition of tumor growth by l-deprenyl involves neural-immune interactions in rats with spontaneously developing mammary tumors. Anticancer Res 19:5023–5028PubMed
Zurück zum Zitat ThyagaRajan S, Madden KS, Stevens SY, Felten DL (2000) Antitumor effect of l-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogen-induced mammary tumors. J Neuroimmunol 109:95–104PubMedCrossRef ThyagaRajan S, Madden KS, Stevens SY, Felten DL (2000) Antitumor effect of l-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogen-induced mammary tumors. J Neuroimmunol 109:95–104PubMedCrossRef
Zurück zum Zitat Wu RF, Ichikawa Y (1995) Inhibition of 1-methyl-4.phenyl-1,2,3,6-tetrahydropyridine metabolic activity of porcine FAD-containing monooxygenase activity by selective monoamine oxidase-B inhibitors. FEBS Lett 358:145–148PubMedCrossRef Wu RF, Ichikawa Y (1995) Inhibition of 1-methyl-4.phenyl-1,2,3,6-tetrahydropyridine metabolic activity of porcine FAD-containing monooxygenase activity by selective monoamine oxidase-B inhibitors. FEBS Lett 358:145–148PubMedCrossRef
Zurück zum Zitat Youdim MB, Weinstock M (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech Ageing Dev 123:1081–1086PubMedCrossRef Youdim MB, Weinstock M (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech Ageing Dev 123:1081–1086PubMedCrossRef
Zurück zum Zitat Youdim MB, Wadia A, Tatton W, Weinstock M (2006) The antiParkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939:450–458CrossRef Youdim MB, Wadia A, Tatton W, Weinstock M (2006) The antiParkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939:450–458CrossRef
Metadaten
Titel
Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes
verfasst von
Eszter Lajkó
Lívia Polgár
Orsolya Láng
József Lengyel
László Kőhidai
Kálmán Magyar
Publikationsdatum
01.05.2012
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 5/2012
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-011-0735-1

Weitere Artikel der Ausgabe 5/2012

Journal of Neural Transmission 5/2012 Zur Ausgabe

Biological Psychiatry - CONy Pro/Con debate

Should magnesium be given to every migraineur? No

Biological Psychiatry - CONy Pro/Con debate

Why all migraine patients should be treated with magnesium

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.